Heme oxygenase inhibition by α-(1H-imidazol-1-yl)-ω-phenylalkanes: effect of introduction of heteroatoms in the alkyl linker.

Several α-(1H-imidazol-1-yl)-ω-phenylalkanes were synthesized and evaluated as novel inhibitors of heme oxygenase (HO). These compounds were found to be potent and selective for the stress-induced isozyme HO-1, showing mostly weak activity toward the constitutive isozyme HO-2. The introduction of an oxygen atom in the alkyl linker produced analogues with decreased potency toward HO-1, whereas the presence of a sulfur atom in the linker gave rise to analogues with greater potency toward HO-1 than the carbon-containing analogues. The most potent compounds studied contained a five-atom linker between the imidazolyl and phenyl moieties, whereas the most HO-1-selective compounds contained a four-atom linker between these groups. The compounds with a five-atom linker containing a heteroatom (O or S) were found to be the most potent inhibitors of HO-2; 1-(N-benzylamino)-3-(1H-imidazol-1-yl)propane dihydrochloride, with a nitrogen atom in the linker, was found to be inactive.

Specificity of ß1,4-galactosyltransferase inhibition by 2-naphthyl 2-butanamido-2-deoxy-1-thio-ß-D-glucopyranoside.

Inhibitors of Galactosyltransferase (GalT) have the potential of reducing the amounts of adhesive carbohydrates on secreted and cell surface-bound glycoproteins. We recently found a potent inhibitor of ß4GalT, 2-naphthyl 2-butanamido-2-deoxy-1-thio-ß-D-glucopyranoside (compound 612). In this work, we have tested compound 612 for the specificity of its inhibition and examined its effect on GalT, and on GlcNAc- and GalNAc-transferases in homogenates of different cell lines, as well as on recombinant glycosyltransferases. Compound 612 was found to be a specific inhibitor of ß4GalT. The specificity of recombinant human ß3GalT5 that also acts on GlcNAc-R substrates, revealed similarities to bovine milk ß4GalT. However, 612 was a poor substrate and not an inhibitor for ß3GalT5. To further determine the specific structures responsible for the inhibitory property of 612, we synthesized (2-naphthyl)-2-butanamido-2-deoxy-ß-D-glucopyranosylamine (compound 629) containing nitrogen in the glycosidic linkage, and compared it to other naphthyl and quinolinyl derivatives of GlcNAc as substrates and inhibitors. Compound 629 was a substrate for both ß4GalT and ß3GalT5. This suggests that properties of 612 other than the presence of the naphthyl ring alone were responsible for its inhibitory action. The results suggest a usefulness of 612 in specifically blocking the synthesis of type 2 chains and thus epitopes attached to type 2 chains. In addition, 612 potently inhibits ß4GalT in cell homogenates and thus allows assaying ß3GalT activity in the presence of ß4GalT.

Anti-Plasmodium activity of imidazolium and triazolium salts.

We have previously reported that tetrazolium salts were both potent and specific inhibitors of Plasmodium replication, and that they appear to interact with a parasite component that is both essential and conserved. The use of tetrazolium salts in vivo is limited by the potential reduction of the tetrazolium ring to form an inactive, neutral acyclic formazan. To address this issue imidazolium and triazolium salts were synthesized and evaluated as Plasmodium inhibitors. Many of the imidazolium and triazolium salts were highly potent with active concentrations in the nanomolar range in Plasmodium falciparum cultures, and specific to Plasmodium with highly favorable therapeutic ratios. The results corroborate our hypothesis that an electron-deficient core is required so that the compound may thereby interact with a negatively charged moiety on the parasite merozoite; the side groups in the compound then form favorable interactions with adjacent parasite components and thereby determine both the potency and selectivity of the compound.

Drug evolution concept in drug design: 1. Hybridization method.

A novel concept, "drug evolution", is proposed to develop chemical libraries that have a high probability of finding drugs or drug candidates. It converts biological evolution into chemical evolution. In this paper, we present "hybridization" drug evolution, which is the equivalent of sexual recombination of parental genomes in biological evolution. The hybridization essentially shuffles the building blocks of the parent drugs and ought to drug(s); no drug evolution can otherwise occur. We hybridized two drugs, benzocaine and metoclopramide and generated 16 molecules that include the parent drugs, four known drugs, and two molecules whose therapeutic activities are reported. The unusually high number of drugs and drug candidates in the library encourages high expectations of finding new drug(s) or drug candidate(s) within the remaining eight compounds. Interestingly, the therapeutic applications of the eight drugs or drug candidates in the library are fairly diverse as 38 therapeutic applications and 25 molecular targets are counted. Therefore, the library fits as a general chemical library for unspecified therapeutic activities. The hybridization of other two drugs, aspirin and cresotamide, is also described to demonstrate the generality of the method.

Detection of chiral perturbations in ferroelectric liquid crystals induced by an atropisomeric biphenyl dopant.

The atropisomeric dopant 2,2',6,6'-tetramethyl-3,3'-dinitro-4,4'-bis[(4-nonyloxybenzoyl)oxy]biphenyl (1) induces a ferroelectric SmC phase when doped into the SmC liquid crystal hosts 2-(4-butyloxyphenyl)-5-octyloxypyrimidine (PhP1) and (+/-)-4-[(4-methylhexyl)oxy]phenyl 4-decyloxybenzoate (PhB). The propensity of dopant 1 to induce a spontaneous polarization (polarization power) is much higher in PhP1 than in PhB (1555 nC/cm(2) vs <35 nC/cm(2)), which is attributed to a greater propensity of 1 to undergo chirality transfer via core-core interactions with PhP1. In previous work, we postulated that a chiral perturbation exerted by 1 in PhP1 amplifies the polarization power of the dopant by causing a chiral distortion of the mean field potential (binding site) constraining the dopant in the SmC host, as described by the Chirality Transfer Feedback (CTF) model. To test the validity of the CTF model, and to provide a more direct assessment of the chiral perturbation exerted by dopant 1 on surrounding host molecules, we measured the effect of 1 on the polarization power of other chiral dopants acting as probes. In one series of experiments, (S,S)-5-(2,3-difluorooctyl)-2-(4-octylphenyl)pyridine (MDW950) and (S)-4-(1-methylheptyloxy)phenyl 4-decyloxybenzoate (4), which mimic the structures of PhP1 and PhB, were used as probes. In another series of experiments, the atropisomeric dopant 2,2',3,3',6,6'-hexamethyl-4,4'-bis[(4-nonyloxybenzoyl)oxy]biphenyl (2) was used as probe in PhP1. The results of the probe experiments suggest that dopant 1 exerts a much stronger chiral perturbation in PhP1 than in PhB. More significantly, the results of experiments using 2 as probe show that the chiral perturbation exerted by 1 can amplify the polarization power of another atropisomeric dopant, thus providing the first experimental evidence of the CTF effect.

Drug evolution: p-aminobenzoic acid as a building block.

The core or the building block is an important component in drug development. In this article, we propose and review p-aminobenzoic acid (PABA) as a building block used in the design of drugs or drug candidates. PABA is frequently found as a structure moiety in drugs. For example, in a database of 12,111 commercial drugs, 1.5% (184 drugs) were found to contain the PABA moiety. These drugs have a wide range of therapeutic uses, such as: sun-screening, antibacterial, antineoplastic, local anesthetic, anticonvulsant, anti-arrhythmic, anti-emetic, gastrokinetic, antipsychotic, neuroleptic, and migraine prophylactic. This article reviews the molecular targets and the mechanisms of these activities. Drugs containing PABA also show a wide range of structural diversity. Of the 184 PABA containing drugs identified, 95 different substitutions were found at the carboxylic group and 61 were found at the amino group of the building block. Substitution on the aromatic ring was also diverse. 13, 3, and 13 different side chains were found to modify positions 2, 3 and 5 of the aromatic ring respectively. In some drugs, the amino group is further substituted to form tertiary amine (4 different side chains). Substitutions at the carboxyl and amino groups of PABA are particularly suitable for the generation of combinatorial libraries. Just by reshuffling the identified side chains of the 184 PABA containing drugs, 4.5 million compounds can be generated. Consequently, PABA fits well as a building block for a general chemical library of "drug-like" molecules with a wide range of functional and structural diversity.